Principal Financial Group Inc. raised its stake in Natus Medical Inc. (NASDAQ:BABY) by 2.6% during the second quarter, Holdings Channel reports. The institutional investor owned 233,643 shares of the company’s stock after buying an additional 5,968 shares during the period. Principal Financial Group Inc. owned approximately 0.72% of Natus Medical worth $8,832,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of BABY. Barclays PLC acquired a new stake in Natus Medical during the first quarter valued at approximately $959,000. Bayesian Capital Management LP acquired a new stake in Natus Medical during the first quarter valued at approximately $276,000. Invictus RG acquired a new stake in Natus Medical during the first quarter valued at approximately $148,000. Kennedy Capital Management Inc. increased its stake in Natus Medical by 88.4% in the first quarter. Kennedy Capital Management Inc. now owns 202,553 shares of the company’s stock valued at $7,784,000 after buying an additional 95,022 shares in the last quarter. Finally, Lazard Asset Management LLC increased its position in shares of Natus Medical by 6.2% in the first quarter. Lazard Asset Management LLC now owns 135,758 shares of the company’s stock worth $5,217,000 after buying an additional 7,951 shares during the period. Institutional investors and hedge funds own 88.00% of the company’s stock.

Institutional Ownership by Quarter for Natus Medical (NASDAQ:BABY)

Natus Medical Inc. (NASDAQ:BABY) opened at 39.70 on Wednesday. The firm has a market cap of $1.29 billion, a P/E ratio of 34.22 and a beta of 0.78. Natus Medical Inc. has a 12 month low of $29.54 and a 12 month high of $51.05. The stock has a 50 day moving average of $41.06 and a 200-day moving average of $37.00.

Natus Medical (NASDAQ:BABY) last released its quarterly earnings results on Wednesday, October 19th. The company reported $0.39 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.05. Natus Medical had a net margin of 10.20% and a return on equity of 13.82%. The business had revenue of $90.90 million for the quarter, compared to analyst estimates of $89.94 million. During the same period last year, the firm earned $0.39 earnings per share. Natus Medical’s revenue for the quarter was down 3.9% compared to the same quarter last year. Equities research analysts predict that Natus Medical Inc. will post $1.55 earnings per share for the current fiscal year.

A number of brokerages have recently issued reports on BABY. Raymond James Financial Inc. upgraded shares of Natus Medical from a “market perform” rating to an “outperform” rating and set a $46.00 price target on the stock in a research report on Tuesday, September 13th. Zacks Investment Research downgraded shares of Natus Medical from a “buy” rating to a “hold” rating in a research report on Wednesday, September 28th. Finally, Benchmark Co. began coverage on shares of Natus Medical in a research report on Tuesday, October 4th. They issued a “buy” rating and a $55.00 price target on the stock.

In other news, insider James B. Hawkins bought 10,000 shares of the firm’s stock in a transaction on Wednesday, September 28th. The shares were purchased at an average cost of $38.48 per share, with a total value of $384,800.00. Following the acquisition, the insider now directly owns 459,725 shares in the company, valued at $17,690,218. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 4.80% of the company’s stock.

About Natus Medical

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

5 Day Chart for NASDAQ:BABY

Want to see what other hedge funds are holding BABY? Visit to get the latest 13F filings and insider trades for Natus Medical Inc. (NASDAQ:BABY).

Receive News & Ratings for Natus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Inc. and related companies with's FREE daily email newsletter.